Myomo Q4 Beats Estimates with $11.35M Revenue and $0.08 EPS Loss
Myomo posted a Q4 loss of $0.08 per share versus a consensus estimate loss of $0.09 and delivered an 11.86% revenue surprise with $11.35 million in sales, down from $12.07 million a year prior. Shares have declined 12% year-to-date against the S&P 500’s 1.5% drop.
1. Q4 Financial Results
Myomo reported a GAAP loss of $0.08 per share for the quarter ended December 2025 versus a consensus loss of $0.09 per share, and generated $11.35 million in revenue compared to $12.07 million in the same period a year earlier.
2. Earnings and Revenue Surprises
The company delivered a 5.88% upside to EPS estimates and an 11.86% revenue surprise, marking two EPS beats and four revenue beats over the last four quarters.
3. Stock Performance
Myomo shares have fallen approximately 12% since January, underperforming the S&P 500’s 1.5% decline over the same period.
4. Outlook and Estimates
Analyst consensus for the next quarter forecasts a $0.09 per share loss on $10.3 million in revenue, with full-year estimates at a $0.29 loss on $44.85 million in sales; the medical products industry sits in the bottom 40% of peers by performance.